AKT1 and neoplasm: Most research on PD-1/PD-L1 binding has been in the field of oncology, focusing on tumor-infiltrating lymphocytes (TILs), where PD-1 binds to tumor PD-L1, activating the Akt/mTORC1 signaling cascade in the PD-L1-expressing target.